Galapagos in the news

Galapagos intends to wind down its cell therapy division, cutting 365 jobs and closing multiple sites to focus on sustainable growth.

Galapagos reorganizes its Board to enhance focus on business development and innovative drug pipeline expansion.

Galapagos will present new Phase 3 data on its selective TYK2 inhibitor GLPG3667 for autoimmune diseases at a major rheumatology conference.

Galapagos is scaling back its cell therapy operations, risking 50 jobs, and reconsidering its strategic approach after shelving a planned company split.

Galapagos is progressing in selling its cell therapy unit, aiming to focus on advanced projects aligned with Gilead's priorities, with a decision expected by early November.

Galapagos is cutting hundreds of jobs and halting its promising CAR-T cancer therapy program after multiple setbacks, leaving patients and investors in a difficult position.

RBC Capital increased its price target for Galapagos NV to $28 after the termination of the company's CAR-T program and subsequent re-evaluation of its valuation, noting the company is streamlining operations and managing costs.

Paulo Fontoura is leaving Lakefront Biotherapeutics to become Global Head of Research & Development Pharma at Sanofi.

Galapagos, now Lakefront Biotherapeutics, has undergone multiple strategic shifts, ending up as a smaller company with substantial cash reserves, now largely betting its future on the success of the drug gamgertamig acquired through a deal with Gilead.

Rabo Securities issues a buy rating for Galapagos while warning of high stock price volatility.

Lakefront Biotherapeutics, formerly Galapagos, appointed Eric Hedrick as Chief Medical Officer to lead its clinical R&D following the Ouro Medicines acquisition.

Lakefront Biotherapeutics appointed Eric Hedrick as Chief Medical Officer to lead its R&D pipeline following the Ouro Medicines acquisition.

Lakefront has completed a billion-dollar acquisition to integrate a new inflammatory drug candidate into its clinical pipeline through a partnership with Gilead.

Galapagos CEO discusses potential takeover risks and upcoming clinical trial results that may trigger an acquisition by partner AbbVie.

A massive revenue drop due to the Gilead contract ending is being offset by a strategic pivot to autoimmune therapies and an upcoming name change to Lakefront Biotherapeutics.

Galapagos reported a sharp revenue decline due to expiring agreements but turned a profit through financial gains while rebranding as Lakefront Biotherapeutics to focus on its new autoimmune pipeline.

Galapagos is launching Lakefront Biotherapeutics in Chicago to lead its strategic shift in medicine development.

Galapagos has rebranded as Lakefront Biotherapeutics following a leadership change and a strategic pivot away from cell therapy toward a co-development deal with Gilead.

Galapagos is undergoing a major strategic transformation by winding down its cell therapy operations and divesting its Jyseleca business to focus on new innovative medicine development.

Operating expense data excluding cost of goods sold for Galapagos NV.